Frequent activation of mammalian target of rapamycin in primary lung adenocarcinoma and preinvasive lesion

Basic and Applied Pathology

Volumn 4, Issue 3, 2011, Pages 78-85

  Kim, Younghye ^a   Jeong, Hoiseon ^a   Kim, Aeree ^a   Kim, Han Kyeom ^a   Shin, Bong Kyung ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Epidermal growth factor receptor; Lung; Mammalian target of rapamycin; Phosphatase and tensin homolog deleted on chromosome ten

Indexed keywords

EID: 80053165916     PISSN: None     EISSN: 17559294     Source Type: Journal    
DOI: 10.1111/j.1755-9294.2011.01108.x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. National Cancer Information Center [Internet]. Incidence rate of cancer. Goyang National Cancer Information Center, [updated 2010 May 18; cited 2010 Aug 30]. Available from: .
3. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-6.
4. West KA, Linnoila IR, Belinsky SA, Harris CC, Dennis PA. Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res 2004; 64: 446-51.
5. Kim YC, Kwon YS, Oh IJ et al National survey of lung cancer in Korea, 2005. J Lung Cancer 2007; 6: 67-73.
6. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 424-30.
7. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 2008; 13: 139-47.
8. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005; 11: 353-61.
9. Memmott RM, Dennis PA. The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clin Cancer Res 2010; 16: 4-10.
10. Noguchi M. Stepwise progression of pulmonary adenocarcinoma: clinical and molecular implications. Cancer Metastasis Rev 2010; 29: 15-21.
11. Yoshida Y, Shibata T, Kokubu A et al Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. Lung Cancer 2005; 50: 1-8.
12. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, 3rd edn. Lyon IARC Press, 2004.
13. Noguchi M, Shimosato Y. The development and progression of adenocarcinoma of the lung. Cancer Treat Res 1995; 72: 131-42.
14. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th edn. New York Springer, 2009.
15. An J, Jeong H, Lee Y, Woo SU, Seo JH, Kim A. Phosphorylated Akt and phosphorylated mTOR expression in breast invasive carcinomas: analysis of 530 cases. J Breast Cancer 2010; 13: 337-48.
16. Dobashi Y, Suzuki S, Matsubara H, Kimura M, Endo S, Ooi A. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 2009; 115: 107-18.
17. Darb-Esfahani S, Faggad A, Noske A et al Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 2009; 135: 933-41.
18. Suzuki S, Dobashi Y, Sakurai H, Nishikawa K, Hanawa M, Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: an immunohistochemical and fluorescence in situ hybridization study. Cancer 2005; 103: 1265-73.
19. Pence JC, Kerns BJ, Dodge RK, Iglehart JD. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 1993; 128: 1382-90.
20. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, Iglehart JD, Marks JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995; 55: 51-6.
21. Anagnostou VK, Bepler G, Syrigos KN et al High expression of mammalian target of rapamycin is associated with better outcome for patients with early stage lung adenocarcinoma. Clin Cancer Res 2009; 15: 4157-64.
22. Soria JC, Lee HY, Lee JI et al Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002; 8: 1178-84.
23. Awaya H, Takeshima Y, Furonaka O, Kohno N, Inai K. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol 2005; 58: 1076-80.
24. West KA, Brognard J, Clark AS et al Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111: 81-90.
25. Tsao AS, McDonnell T, Lam S et al Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 2003; 12: 660-4.
26. Nakamura H, Kawasaki N, Taguchi M, Kabasawa K. Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 2006; 61: 140-5.
27. Silvestri GA, Rivera MP. Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists. Chest 2005; 128: 3975-84.
28. Pastorino U, Andreola S, Tagliabue E et al Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-65.
29. D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Harpole DH Jr. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999; 117: 736-43.
30. Lai WW, Chen FF, Wu MH et al Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg 2001; 72: 1868-76.